Skip to search formSkip to main contentSkip to account menu

ACP 103

Known as: ACP-103, ACP103 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
The concept that the efficacy of all antipsychotic drugs (APDs) can be explained by their action on dopamine (DA) D2 receptors is… 
Highly Cited
2010
Highly Cited
2010
Psychotic symptoms occur in up to 40% of patients with Parkinson's disease (PD). Clozapine and quetiapine, two atypical… 
Review
2010
Review
2010
ObjectiveTo review the evidence that agents which preferentially affect serotonin (5-HT) attenuate the ability of N-methyl-D… 
2008
2008
The mechanisms underlying the clinical properties of atypical antipsychotics have been postulated to be mediated, in part, by… 
Highly Cited
2007
Highly Cited
2007
Dopamine D2 receptor antagonism contributes to the therapeutic action of antipsychotic drugs (APDs) but also produces undesirable… 
2007
2007
The pharmacokinetics, safety, and tolerability of ACP‐103, a selective serotonin 5‐HT2A receptor inverse agonist, were evaluated… 
Highly Cited
2006
Highly Cited
2006
The in vitro and in vivo pharmacological properties of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2… 
Review
2006
Review
2006
  • C. Roberts
  • Current opinion in investigational drugs
  • 2006
  • Corpus ID: 21495202
ACADIA Pharmaceuticals is developing ACP-103, lead compound in a series of 5-HT2A inverse agonists, as a potential antipsychotic… 
Highly Cited
2005
Highly Cited
2005
RationalAtypical antipsychotic drugs (APDs) such as clozapine, olanzapine, quetiapine, risperidone, and ziprasidone are serotonin…